-
1 Comment
Median Technologies SA is currently in a long term uptrend where the price is trading 24.0% above its 200 day moving average.
From a valuation standpoint, the stock is 94.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 14.7.
Based on the above factors, Median Technologies SA gets an overall score of 2/5.
| CurrencyCode | EUR |
|---|---|
| Sector | Healthcare |
| Industry | Medical Devices |
| Exchange | PA |
| ISIN | FR0011049824 |
| Market Cap | 242M |
|---|---|
| Beta | 0.5 |
| Target Price | 10 |
| PE Ratio | None |
| Dividend Yield | None |
Median Technologies SA engages in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development with operations spanning in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iSee for imaging services in clinical trials; eyonis for non-invasive diagnostic tests based on imaging for the diagnosis and treatment of patients suffering from cancer; and iCRO, a central imaging service and AI-powered Imaging Lab. Also, the company focuses on the oncology clinical trials market and the cancer patient care market. The company was founded in 2002 and is based in Valbonne, France.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALMDT.PA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026